TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Active virus carriers in HCW
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CAPS-5 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PCL-5 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tacrolimus area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported health and wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diversity and steady state of the stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of Deep Vein Thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Serum Lp-PLA2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glucagon secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Circulating (blood) (poly)phenols
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Urinary (poly)phenols
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Faecal (poly)phenols
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Degree and extent of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Disruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of the Level of Acute Kidney Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage Change in Flow-Mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reflux in ovarian veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of patients meeting the MCID for VAS Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Fibromyalgia Impact
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Depression and Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Usability of the computer-based symptom reporting system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-deemed usefulness of computer-based symptom reporting system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness of the computer-based symptom reporting system (FACT-G)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Effectiveness of the computer-based symptom reporting system (CDSES-R)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: tolerability of remote ischemic conditioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: feasibility of remote ischemic conditioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of participants diagnosed with panic disorder
Endpoint domain: Mortality/survival
Primary endpoint: Change in score on the Panic Disorder Severity Scale (PDSS-SR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oppositional Defiant Disorder Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peak knee extensor torque change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Peak knee flexor torque change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Discussion with provider about CHD risk reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stated plans for CHD risk reduction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total Body Fat-Free Mass%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tidal Volume delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ICD Shocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recovery of physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients with adequate colon cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Absolute difference in propofol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time from surgery to intensive care unit discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Self-perceived improvements in ability to manage medications
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intraoperative Remifentanil Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Late respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventilator acquired pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Early pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Retinal Nerve Fibre Layer Thickness Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Monitoring of local and systemic adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in brain activation in dorsolateral prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with and types of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation of 68Ga-DOTA-FAPI PET/MR parameters and liver fibrosis progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Epicardial adipose tissue (EAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in Vascular Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Prevalence rate of probable RBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weighted prevalence rate of confirmed RBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post contrast myocardial T1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax for Lomitapide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax for Lomitapide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t for Lomitapide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QOL) - late bowel function
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: No death within 30 days after surgery
Endpoint domain: Mortality/survival
Primary endpoint: No adverse cardiovascular and cerebrovascular events within one year after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: No reoperative intervention associated with aorta occurred within one year after surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diagnostic markers of PCOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Peri-implant marginal bone level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of en-masse retraction of upper anterior teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the anteroposterior movement of the molar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the inter-canine width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the inter-molar width at 5 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hb Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Finger Tapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Local scored atopic dermatitis (SCORAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lamellar Body Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT)
Endpoint domain: Mortality/survival
Primary endpoint: 3-year Progression-free Survival (PFS) Rate of Patients With Localized CNS Germinoma
Endpoint domain: Mortality/survival
Primary endpoint: Neurocognitive Function Using the ALTE07C1 Protocol
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of Active Subjects Achieving Overall Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Experiencing Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative morphine consumption change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Satisfaction regarding aesthetic results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Tolerated Dose (MTD) of BI 891065
Endpoint domain: Adverse events/effects
Primary endpoint: AUC after infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Progression Free Survival (PFS) for First Line Medication
Endpoint domain: Mortality/survival
Primary endpoint: Progression Free Survival (PFS) for Crossover Medication
Endpoint domain: Mortality/survival
Primary endpoint: Pain Assessment by Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Evidence Based Practice knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Alpha motor neuron excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Kinesiophobia Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression Severity Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bacterial Reduction - Groin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incremental Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total score of the Young Mania Rating Scale (YMRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-Related Functional Impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Instrumental acoustic voice parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of Dysphagia Patients Experience (Burden)
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Degree of Dysphagia Patients Experience (Eating Desire)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Degree of Dysphagia Patients Experience (Fatigue)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Stopping air and water passage during middle ear infection treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retrieval of Index Lesion and Magseed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Neurofilament
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urinary p75 neurotrophin receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Monocyte CD14 receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ApoB/ApoA1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: TG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Proportion of Patients Identified as Cured
Endpoint domain: Mortality/survival
Primary endpoint: Common Carotid Intima-media Thickness (cIMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: post operative edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in pain score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Wong Baker Face Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peptic ulcer bleeding control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MADRS Rating Scale Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fetal Heart Rate Positive Percentage Agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity measured by Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Antibody Titers >= 1:8 Against Meningococcal Serogroups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Brain penetration of [11C]lapatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain tumour penetration of [11C]lapatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of Genetic Testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical and Patient Reported Outcomes Following Genetic Test Results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Moderate or severe COPD exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Event related survival
Endpoint domain: Mortality/survival
Primary endpoint: hypoxia volume (HV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree (maximum ratio [Rmax])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serious complications of COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in SAO2<92%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in viral titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sustained symptom resolution
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical Performance Test Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-day Utility Weighted Modified Rankin Scores (UW-mRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of P2Y12 receptor inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PCR-based P. falciparum and P. vivax parasite prevalence in sampled HCCAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HS-RDT/RDT-based test positivity rate in village and forest-based reactive case detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Survival of Participants
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Non-motor Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-week progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Anti-Hepatitis B Surface (Anti-HBs) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: B cell activation after allergen challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: M1 prime related biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Distinguishing between taste types using facial expressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical placement of cochlear implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of intrusive memories
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in marital satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in family functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in typically developing siblings' depressive symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Coefficient of variation of tear film osmolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Strength & Muscle Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline in Energy & Fatigue Symptoms/Psychological Function
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in average pain rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility rate of APBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Composite measurement of Pharmacokinetic parameters (Cmax, AUCt, AUCINF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Aneurysmal occlusion of the treated target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural device-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and Severity of Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Discontinued Treatment due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Self Efficacy for Cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Induction-abortion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Progression of Albuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: efficacy of itacitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Extubation Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of opioid use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of alcohol and marijuana use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CSF Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in platelet p-selectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Leukocyte-platelet aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of cognitive functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Serum concentrations of omentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of ASC41
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in psychological stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: therapeutic effect on bleeding ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reduced need for endoscopic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: improved clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-procedure Infectious Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Inflammation of gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding from gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque in the gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esthetic Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of major CVD events
Endpoint domain: Mortality/survival
Primary endpoint: Change in Psychomotor Vigilance Task (PVT) Median Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes